Pretransplantation characteristics of patients
| Pt. . | Study UPN . | Sex . | Age, y . | Group* . | Primary organ† . | DLCO/FVC‡ . | Serum creatinine . | mRSS . | Disease duration, mo . | Scl-70 +ve . | Prior therapy . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | FH11956 | F | 47 | 1 | R | 76/74 | 1.4 | 47 | 38 | No | Hcq, St, D-pen, CSA |
| 2 | FH12946 | M | 38 | 1 | P | 48/72 | 1 | 29 | 30 | Yes | Hcq, CSA, St |
| 3 | FH13316 | F | 23 | 1 | P | 57/62 | 0.7 | 30 | 28 | Yes | Mtx, D-pen, Ctx, St |
| 4 | FH13483 | F | 40 | 1 | P | 47/75 | 0.5 | 32 | 22 | Yes | IVIG, St |
| 5 | FH13833 | F | 39 | 1 | P | 46/77 | 0.5 | 30 | 35 | Yes | CSA, D-pen |
| 6 | FH14767 | F | 61 | 1 | P | 67/83 | 0.8 | 35 | 7 | No | St, Cy |
| 7 | FH14709 | F | 56 | 1 | P | 52/76 | 0.5 | 50 | 9 | No | D-pen |
| 8 | UM 1 | F | 40 | 1 | P | 62/69 | 0.8 | 39 | 15 | Yes | Mtx |
| 9 | FH15570 | F | 49 | 2 | P | 45/75 | 0.8 | 14 | 13 | Yes | St, Aza, Mtx |
| 10 | KCI-1 | F | 27 | 2 | P | 66/78 | 0.9 | 3 | 18 | No | Mtx, St |
| 11 | FH16089 | F | 37 | 1 | P | 57/87 | 0.6 | 40 | 11 | No | St, Mtx, Rl |
| 12 | FH15782 | F | 55 | 1 | P | 57/64 | 0.4 | 27 | 29 | No | St, Cy |
| 13 | KCI-2 | M | 48 | 1 | P | 47/65 | 0.9 | 24 | 20 | Yes | Cy, St |
| 14 | UM-2 | M | 23 | 1 | P | 66/103 | 1 | 18 | 4 | Yes | None |
| 15 | FH15735 | F | 23 | 1 | P | 84/65 | 0.6 | 31 | 34 | ND | D-pen, St, Cy |
| 16 | KCI-3 | F | 42 | 1 | P | 56/67 | 1.3 | 36 | 41 | No | Mtx |
| 17 | FH16891 | F | 28 | 1 | P | 47/54 | 0.6 | 43 | 19 | Yes | St, D-pen |
| 18 | FH16855 | F | 40 | 1 | P | 69/66 | 0.6 | 19 | 28 | Yes | Enb |
| 19 | LLU-1 | F | 34 | 1 | P | 72/61 | 0.4 | 32 | 16 | No | Hcq, Mtx |
| Median | 40 | 57/72 | 0.7 | 31 | 20 |
| Pt. . | Study UPN . | Sex . | Age, y . | Group* . | Primary organ† . | DLCO/FVC‡ . | Serum creatinine . | mRSS . | Disease duration, mo . | Scl-70 +ve . | Prior therapy . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | FH11956 | F | 47 | 1 | R | 76/74 | 1.4 | 47 | 38 | No | Hcq, St, D-pen, CSA |
| 2 | FH12946 | M | 38 | 1 | P | 48/72 | 1 | 29 | 30 | Yes | Hcq, CSA, St |
| 3 | FH13316 | F | 23 | 1 | P | 57/62 | 0.7 | 30 | 28 | Yes | Mtx, D-pen, Ctx, St |
| 4 | FH13483 | F | 40 | 1 | P | 47/75 | 0.5 | 32 | 22 | Yes | IVIG, St |
| 5 | FH13833 | F | 39 | 1 | P | 46/77 | 0.5 | 30 | 35 | Yes | CSA, D-pen |
| 6 | FH14767 | F | 61 | 1 | P | 67/83 | 0.8 | 35 | 7 | No | St, Cy |
| 7 | FH14709 | F | 56 | 1 | P | 52/76 | 0.5 | 50 | 9 | No | D-pen |
| 8 | UM 1 | F | 40 | 1 | P | 62/69 | 0.8 | 39 | 15 | Yes | Mtx |
| 9 | FH15570 | F | 49 | 2 | P | 45/75 | 0.8 | 14 | 13 | Yes | St, Aza, Mtx |
| 10 | KCI-1 | F | 27 | 2 | P | 66/78 | 0.9 | 3 | 18 | No | Mtx, St |
| 11 | FH16089 | F | 37 | 1 | P | 57/87 | 0.6 | 40 | 11 | No | St, Mtx, Rl |
| 12 | FH15782 | F | 55 | 1 | P | 57/64 | 0.4 | 27 | 29 | No | St, Cy |
| 13 | KCI-2 | M | 48 | 1 | P | 47/65 | 0.9 | 24 | 20 | Yes | Cy, St |
| 14 | UM-2 | M | 23 | 1 | P | 66/103 | 1 | 18 | 4 | Yes | None |
| 15 | FH15735 | F | 23 | 1 | P | 84/65 | 0.6 | 31 | 34 | ND | D-pen, St, Cy |
| 16 | KCI-3 | F | 42 | 1 | P | 56/67 | 1.3 | 36 | 41 | No | Mtx |
| 17 | FH16891 | F | 28 | 1 | P | 47/54 | 0.6 | 43 | 19 | Yes | St, D-pen |
| 18 | FH16855 | F | 40 | 1 | P | 69/66 | 0.6 | 19 | 28 | Yes | Enb |
| 19 | LLU-1 | F | 34 | 1 | P | 72/61 | 0.4 | 32 | 16 | No | Hcq, Mtx |
| Median | 40 | 57/72 | 0.7 | 31 | 20 |
Eligibility group as per Table 1.
Primary organ dysfunction for which HDIT was performed. P indicates pulmonary; R, renal.
DLCO corrected for hemoglobin expressed as %; FVC, forced vital capacity expressed as %. FH indicates Fred Hutchinson Cancer Research Center; KCI, Karmanos Cancer Institute; UM, University of Michigan; LLU, Loma Linda University Medical Center; Aza, azathioprine; CSA, cyclosporine; Cy, cyclophosphamide; D-Pen, D-penicillamine; Enb, Enbrel; F, female; Hcq, Hydroxychloroquine; IVIG, intravenous immunoglobulin; M, male; mRSS, modified Rodnan skin score; Mtx, methotrexate; Rl, relaxin; St, corticosteroids.